• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Niagen Bioscience Inc.

    8/8/25 4:05:48 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NAGE alert in real time by email
    S-8 1 ea025141401-s8_niagen.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on August 8, 2025

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8 

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    NIAGEN BIOSCIENCE, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   26-2940963

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    10900 Wilshire Blvd., Suite 600

    Los Angeles, California 90024

    (310) 388-6706

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Niagen Bioscience, Inc. 2017 Equity Incentive Plan

     (Full title of the plan)

     

    Robert Fried

    Chief Executive Officer

    10900 Wilshire Blvd., Suite 600

    Los Angeles, California 90024

    (310) 388-6706

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Ben Orlanski, Esq. 

    Louis Rambo, Esq.

    Proskauer Rose LLP

    2029 Century Park East, Suite 2400

    Los Angeles, CA 90067

    (310) 557-2900

    Ozan Pamir

    Chief Financial Officer

    10900 Wilshire Boulevard, Suite 600

    Los Angeles, CA 90024

    (310) 388-6706

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐  

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is filed pursuant to General Instruction E to Form S-8 by Niagen Bioscience, Inc. (the “Company”) for the purpose of registering an additional 4,750,000 shares of the Company’s common stock, par value $0.001 per share (“common stock”), that were added to the Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended (the “2017 Plan”), pursuant to a share reserve increase approved by the Company’s stockholders on June 24, 2025.  The Company previously registered shares of its common stock for issuance under the 2017 Plan on Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on October 31, 2017 (File No. 333-221246), March 23, 2018 (File No. 333-223889), August 22, 2018 (File No. 333-226972), August 18, 2020 (File No. 333-248104) and June 22, 2023 (File N0. 333-272830) (the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed by the Company with the SEC are incorporated by reference into this Registration Statement:

     

    a)The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 4, 2025 (including the portions of the Company’s definitive proxy statement on Schedule 14A filed on April 29, 2025 incorporated by reference therein);

     

    b)The Company’s Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 7, 2025, and for the quarterly period ended June 30, 2025, filed with the SEC on August 6, 2025;

     

    c)The Company’s Current Reports on Form 8-K filed with the SEC on February 27, 2025, March 19, 2025, June 27, 2025, and July 29, 2025; and

     

    d)The description of the Company’s common stock included in the Company’s Form 8-A filed with the SEC on April 21, 2016, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all of the Company’s reports filed with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, other than current reports furnished under Item 2.02 and Item 7.01 of Form 8-K and any exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to filing a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such reports.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

     

    ITEM 8.EXHIBITS.

     

    Exhibit Number   Description
    4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference from, and filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K (File No. 001-37752) filed with the SEC on March 15, 2018).
    4.2   Certificate of Amendment to the Certificate of Incorporation of the Registrant (incorporated by reference from, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the SEC on April 12, 2016).
    4.3   Certificate of Amendment to the Certificate of Incorporation of the Registrant (incorporated by reference from, and filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the SEC on March 19, 2025).
    4.4   Amended and Restated Bylaws of the Registrant (incorporated by reference from, and filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the SEC on March 19, 2025).
    5.1*   Opinion of Proskauer Rose LLP.
    23.1*   Consent of Crowe LLP.
    23.2*   Consent of Marcum LLP.
    23.3*   Consent of Proskauer Rose LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (contained on the signature page hereto).
    99.1   Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended (incorporated by reference from, and filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37752) filed with the SEC on June 27, 2025).
    107*   Filing Fee Table

     

    *Filed herewith

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on August 8, 2025.

     

      NIAGEN BIOSCIENCE, INC.
         
      By: /s/ Robert Fried
        Robert Fried
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert Fried and Ozan Pamir, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
         
    /s/ ROBERT FRIED   Chief Executive Officer and Director   August 8, 2025
    Robert Fried   (Principal Executive Officer)      
             
    /s/ OZAN PAMIR   Chief Financial Officer    August 8, 2025
    Ozan Pamir   (Principal Financial and Accounting Officer)    
             
    /s/ FRANK JAKSCH JR.     Chairman of the Board and Director     August 8, 2025
    Frank Jaksch Jr.        
             
    /s/ GARY NG   Director   August 8, 2025
    Gary Ng          
             
    /s/ STEVEN RUBIN   Director   August 8, 2025
    Steven Rubin          
             
    /s/ WENDY YU     Director   August 8, 2025
    Wendy Yu        
             
    /s/ KRISTIN PATRICK    Director   August 8, 2025
    Kristin Patrick        
             
    /s/ ANN COHEN   Director   August 8, 2025
    Ann Cohen          
             
    /s/ HAMED SHAHBAZI     Director   August 8, 2025
    Hamed Shahbazi        

      

    II-3

     

    Get the next $NAGE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAGE

    DatePrice TargetRatingAnalyst
    5/27/2025$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $NAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

    Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin

    8/6/25 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

    Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit www.wsw.com. Mr. Fried and Mr. Pamir will also hold one-on-one meetings with instituti

    8/4/25 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug

    7/23/25 8:34:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Shahbazi Hamed

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    7/3/25 10:42:17 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Yu Wing Tak Wendy

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    6/26/25 5:30:41 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Patrick Kristin

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    6/26/25 5:29:03 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Niagen Bioscience with a new price target

    Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00

    5/27/25 9:10:59 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    SEC Filings

    View All

    SEC Form S-8 filed by Niagen Bioscience Inc.

    S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)

    8/8/25 4:05:48 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-8 filed by Niagen Bioscience Inc.

    S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)

    8/8/25 4:05:48 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

    8/6/25 4:06:45 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Financials

    Live finance-specific insights

    View All

    Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

    Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin

    8/6/25 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug

    7/23/25 8:34:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

    Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%,

    5/7/25 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

    Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​ Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology

    4/29/25 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care